Colorectal Cancer (CRC) Withdrawn Phase 1 Trials for Cetuximab (DB00002)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Withdrawn	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02573220	Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer	Treatment	Camptothecin (DB04690) Cetuximab (DB00002) Fluorouracil (DB00544) Irinotecan (DB00762) Leucovorin (DB00650)
NCT03169777	QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC	Treatment	Avelumab (DB11945) Bevacizumab (DB00112) CD-16 NK-92 cells (DB17465) Capecitabine (DB01101) Cetuximab (DB00002) Cyclophosphamide (DB00531) ETBX-011 (DB17464) ETBX-021 (DB17528) ETBX-051 (DB17529) ETBX-061 (DB17530) Fluorouracil (DB00544) Fulvestrant (DB00947) GI-4000 (DB05698) GI-6207 (DB17532) GI-6301 (DB17533) Leucovorin (DB00650) Nivolumab (DB09035) Nogapendekin alfa (DB18740) Omega-3-acid ethyl esters (DB09539) Oxaliplatin (DB00526) Paclitaxel (DB01229)
NCT02630420	Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer	Treatment	Cetuximab (DB00002) Savolitinib (DB12048)
NCT04464967	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers	Treatment	Cetuximab (DB00002) Natural Killer Cell (DB15721) SNK01 (DB22344) Trastuzumab (DB00072)
NCT01960023	Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer	Treatment	Cetuximab (DB00002) Neratinib (DB11828)